AFP and hepatocellular carcinoma: For BCLC stage 0 HCC patients, the sensitivity (95% CI) of AFP was 34.62% (17.94%, 55.64%), and the sensitivity (95% CI) of tRF‐3a‐Pro was 73.08% (51.95%, 87.65%) (Figure 3D).